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Creatine serves as fast energy buffer in organs of high-energy demand such as brain and
skeletal muscle. L-Arginine:glycine amidinotransferase (AGAT) and guanidinoacetate
N-methyltransferase are responsible for endogenous creatine synthesis. Subsequent
uptake into target organs like skeletal muscle, heart and brain is mediated by the
creatine transporter (CT1, SLC6A8). Creatine deficiency syndromes are caused by
defects of endogenous creatine synthesis or transport and are mainly characterized
by intellectual disability, behavioral abnormalities, poorly developed muscle mass, and
in some cases also muscle weakness. CT1-deficiency is estimated to be among
the most common causes of X-linked intellectual disability and therefore the brain
phenotype was the main focus of recent research. Unfortunately, very limited data
concerning muscle creatine levels and functions are available from patients with
CT1 deficiency. Furthermore, different CT1-deficient mouse models yielded conflicting
results and detailed analyses of their muscular phenotype are lacking. Here, we report
the generation of a novel CT1-deficient mouse model and characterized the effects
of creatine depletion in skeletal muscle. HPLC-analysis showed strongly reduced
total creatine levels in skeletal muscle and heart. MR-spectroscopy revealed an
almost complete absence of phosphocreatine in skeletal muscle. Increased AGAT
expression in skeletal muscle was not sufficient to compensate for insufficient creatine
transport. CT1-deficient mice displayed profound impairment of skeletal muscle function
and morphology (i.e., reduced strength, reduced endurance, and muscle atrophy).
Furthermore, severely altered energy homeostasis was evident on magnetic resonance
spectroscopy. Strongly reduced phosphocreatine resulted in decreased ATP/Pi levels
despite an increased inorganic phosphate to ATP flux. Concerning glucose metabolism,
we show increased glucose transporter type 4 expression in muscle and improved
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glucose clearance in CT1-deficient mice. These metabolic changes were associated
with activation of AMP-activated protein kinase – a central regulator of energy
homeostasis. In summary, creatine transporter deficiency resulted in a severe muscle
weakness and atrophy despite different compensatory mechanisms.
Keywords: creatine transporter, skeletal muscle, energy metabolism, in vivo magnetic spectroscopy,
L-arginine:glycine amidinotransferase (AGAT), guanidinoacetate N-methyltransferase (GAMT), glycine
amidinotransferase (GATM), Slc6a8
INTRODUCTION
Energy supply for muscle contraction is provided by
breakdown of adenosine triphosphate (ATP), which is
replenished continuously by anaerobic glycolysis or oxidative
phosphorylation. The (P)Cr system serves as rapid energy buffer
to maintain constant ATP levels and mediates subcellular high-
energy phosphate transfer. Therefore, high (P)Cr levels are found
in skeletal muscle in concentrations up to 20–40 mM (Wyss
and Kaddurah-Daouk, 2000). As non-enzymatic degradation of
creatine to creatinine takes place at a daily rate of 1.7% (Wyss and
Kaddurah-Daouk, 2000), the Cr pool has to be replenished via
dietary intake or endogenous Cr synthesis. AGAT (EC 2.1.4.1)
and GAMT (EC 2.1.1.2) are responsible for Cr synthesis from
arginine, glycine, and S-adenosyl-methionine, which mainly
takes place in kidney and liver. Subsequent uptake of Cr into
organs such as brain, heart, and muscle is mediated by the Cr
transporter (CT1, SLC6A8).
Defects of Cr synthesis or transport due to mutations
in AGAT, GAMT, or SLC6A8 (CT1) genes are associated
with Cr deficiency syndromes that affect brain and muscle
to various degrees (Stockler et al., 2007). Patients with
CT1 deficiency are especially prone to intellectual disability,
behavioral abnormalities and seizures. Mutations in SLC6A8
are relatively frequent and were found in up to 2% of cases
of X-linked intellectual disability (van de Kamp et al., 2014).
Slender habitus and poorly developed muscle mass are the
most striking anthropometric features of CT1 deficiency. Motor
dysfunction can affect CT1-deficient patients, with muscular
hypotonia in 10% and, less common, unspecific myopathic
symptoms (Mancini et al., 2005; Puusepp et al., 2010; van de
Kamp et al., 2014, 2015). Significant amounts of Cr were still
detectable in the skeletal muscle of examined patients and studied
knockout mice. However, a significant reduction of muscle Cr
was only visible in mouse models. The relatively preserved Cr
levels in skeletal muscle of CT1-deficient patients may possibly be
due to endogenous Cr synthesis, non-specific uptake or residual
activity of patients’ mutant CT1 (deGrauw et al., 2003; Pyne-
Geithman et al., 2004; Russell et al., 2014; Baroncelli et al.,
2016).
Abbreviations: AGAT, L-arginine:glycine amidinotransferase; AMPK, AMP-
activated protein kinase; Cr, creatine; CSA, cross-sectional area; CT1, creatine
transporter; GAMT, guanidinoacetate N-methyltransferase; GLUT4, glucose
transporter 4; kf, (pseudo-first order unidirectional) forward rate constant
(for Pi→ATP); MRS, magnetic resonance spectroscopy; PCr, phosphocreatine;
(P)Cr, either phosphocreatine or creatine; Pi, inorganic phosphate; PMEs,
phosphomonoesters.
We previously generated and characterized mouse models
with AGAT and GAMT deficiency (Schmidt et al., 2004; Choe
et al., 2013b). In addition to pronounced CNS and metabolic
phenotypes, these mice displayed impaired muscle strength
and muscle atrophy underlining the role of the (P)Cr system
in skeletal muscle (Torremans et al., 2005; Nabuurs et al.,
2013). Previous studies on CT1-deficient mouse models have
focused on the central nervous system. The muscle phenotype
has not yet been analyzed in detail and the preliminary
characterization generated conflicting results from different
models and methodological approaches (Skelton et al., 2011;
Russell et al., 2014; Baroncelli et al., 2016). Therefore, we
generated and characterized CT1-deficient mice with a focus
on muscle physiology. Our novel CT1-deficient mouse model
revealed (P)Cr deficiency in skeletal muscle associated with
impaired motor function and muscle atrophy, which is in
agreement with previous models (Russell et al., 2014; Baroncelli
et al., 2016). Magnetic resonance spectroscopy experiments were
performed to elucidate the high-energy phosphate metabolism
in skeletal muscle of CT1-deficient mice. Furthermore, glucose
metabolism, enzymes of creatine biosynthesis, and proteins of
oxidative phosphorylation were studied in skeletal muscle of
CT1-deficient mice to elucidate altered pathways.
MATERIALS AND METHODS
Ethics Statement
All animal procedures were conducted in accordance with
institutional and national guidelines and were approved by
the respective local animal ethics committees (Hamburg: 11/89
and 12/86, Nijmegen: RU-DEC2012-184). All experimental
procedures conformed with the Guide for the Care and
Use of Laboratory Animals published by the US National
Institutes of Health (NIH Publication No. 83-123, revised
1996) and were performed in accordance with the ARRIVE
guidelines. Mice used in this study were obtained from
heterozygous matings. CT1-deficient knockout (CT1−/y) mice
and controls were age- and sex-matched littermates. Mice (<5
per cage) were kept in standard cages under a 12–12 h light–
dark cycle, constant temperature, and humidity, and received
standard food and water ad libitum. Chow was essentially
Cr free (R/M-H, Ssniff), as previously shown (Schmidt et al.,
2004).
Generation of CT1-Deficient Mice
In brief, CT1-deficient knockout (CT1−/y) mice were generated
by injection of embryonic stem cells (ESCs) containing a targeted
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CT1 (Slc6a8) locus obtained from the NIH Knock-out Mouse
Program (KOMP, project CSD24513, Slc6a8tm1a(KOMP)Wtsi allele
in ES cell clone EPD0293_6_E05). The ESCs from the parental
line JM8A1.N3 (C57Bl/6N derived; Pettitt et al., 2009) had
been targeted with a targeting-vector (PRPGS00081_A_A09)
consisting of all 13 Slc6a exons with loxP sites flanking
exons 5–8 (Skarnes et al., 2011). The targeted allele contains
an insertion of a beta-galactosidase/lacZ reporter expression
cassette (L1L2_Bact_P) with a splice acceptor site in the intron
between exons 4 and 5, for the detection of Slc6a8 gene
expression. The ESC clone was expanded and microinjected
into C57BL/6J mouse blastocysts, which were then transferred
into pseudo-pregnant C57BL/6J females. Chimeric mice were
mated and gave rise to germ-line transmission of the disrupted
allele. Mice were backcrossed for several generations to
C57BL/6J genetic background with negative selection for
the Rd8 mutation in the F1 generation. Genomic DNA
from mouse-tail or ear biopsies was screened by multiplex
polymerase chain reaction (PCR) following standard protocols.
Sequencing of genomic PCR-products between exons 7 and
8 revealed absence of the 3′ loxP site from the conditional
Slc6a8tm1a(KOMP)Wtsi allele. Therefore, according to the KOMP
mutagenesis scheme, the correct description of the targeted,
non-conditional allele is Slc6a8tm1e(KOMP)Wtsi knock out first
allele.
cDNA Preparation and PCR
Disruption of the murine CT1 gene was confirmed by touch
down PCR of skeletal muscle cDNA using primers binding in
exons 7 and 9 (Figure 1B). Total RNA of knock-down and
wild-type mice was isolated using TRIzol reagent (Invitrogen)
according to the manufacturer’s instructions. DNase I treatment
was performed to remove genomic DNA. Onemicrogram of total
RNAwas used for random primed reverse transcription using the
First Strand cDNA Synthesis Kit (Thermo Scientific) according
to standard protocols. cDNAs were stored at −20◦C. Exon
spanning primers (forward: 5′-tcctggcactcatcaacag-3′, reverse: 5′-
atgaagccctccacacctac-3′) were taken from Ireland et al. (2009)
expecting a 250 bp PCR product in wild-type reaction. Touch
down PCR was performed using the following protocol:
annealing temperature was decreased in 12 steps from 60◦C by
0.5◦C to 54◦C followed by 25 cycles at 54◦C.
Rotarod Test
Mice had to walk on a turning, corrugated rod (3.2 cm in
diameter) (Acceler. Rotarod for mice, Jones & Roberts, TSE
308 systems, Bad Homburg, Germany). The rod was started to
rotate 5 s after the mice were placed onto it. Mice underwent
five trials with an inter-trial-interval (ITI) of 45 min, and
performed at slow, constant speed [i.e., 4 rotations per minute
(rpm)] for a maximum duration of 3 min. Trials 3–5 were
performed with the accelerating rod, starting with 4 rpm up to
40 rpm within 4 min, with a maximum duration of 10 min.
On the following day, a sixth trial was carried out with the
accelerating rod. The performance of the mice was evaluated
by scoring the latency to fall. Experiments were performed
blinded.
Pole Test
The animals were placed on top of a vertical 48.5 cm-long rod
made of rough wood with a diameter of 0.8 cm. To motivate
the mouse to climb down, nesting material of the home cage was
placed at the bottom of the pole. The mouse was placed with its
head facing upward and its four paws grasping the rod. The time
required by the mouse to reach the floor (maximum duration of
each trial was 80 s) was recorded. Each mouse had to perform
three consecutive trials with an ITI of 30 s. The ability of a mouse
to turn 180◦ and climb down with the head pointing downward
was evaluated. When the mouse turned, we recorded whether it
turned at the top (level 1, above 32 cm), at the middle (level 2,
between 32 and 16 cm), or at the bottom of the rod (level 3, below
16 cm). Experiments were performed blinded.
Grip Strength
Maximal grip force was measured using a grip strength meter
(TSE-Systems, Bad Homburg, Germany) as described previously
(Nabuurs et al., 2013). Within each group, the mean grip
force of each mouse was calculated from 15 appropriate trials.
Experiments were performed blinded.
Voluntary Running Wheel
Mice were provided with a vertical, ridged running wheel
(tierisch.de, Flensburg, Germany). The wheels were fixed in the
cage using magnets. Wheel rotation was monitored using a
magnetic read switch attached to a counter. Running distances
were calculated based on the number of rotations within 24 h and
the circumference of the running wheel (41.41 cm). Experiments
were performed blinded.
Muscle Histopathology
Muscle histology was performed as previously described
(Nabuurs et al., 2013). Briefly, mice were transcardially perfused
with 4% formaldehyde in PBS. For morphometry, commonly
stained slides for hematoxylin and eosin (H&E) were used.
Myocyte diameters and CSA were determined in multiple
transverse sections of muscle using ImageJ and calculated by
averaging the data of five images. Determination of myocyte
diameters was performed blinded.
In Vivo 1H MRI and 31P MRS
Male CT1+/y and CT1−/y mice, aged 120–180 days, were placed
in prone position in the magnet bore under anesthesia with
1–2% isoflurane in a 2:1 air/O2 mixture and maintained at
37 ± 1◦C using warm air under control of a rectal sensor
(Luxtron 712, Santa Clara, CA, United States). Breathing rate
(50–70/min) was monitored by a respiratory pad attached to
the chest. Measurements were performed on an 11.7T Biospec
Avance III small animal MR system (Bruker, Biospin, Germany).
The hind legs of mice were placed in a home-built 8 mm
diameter radiofrequency (RF) probe consisting of a 1H and
a 31P coil. Gradient-echo localizer MR images were obtained
in three orthogonal directions followed by localized magnetic
field shimming. Then a 2D gradient-echo image was obtained
of a 2 mm thick transversal slice, positioned at the largest
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CSA distal from the knee joint (FOV = 2 cm × 2 cm, matrix
size = 128 × 128, resolution = 0.156 mm × 0.156 mm,
TR = 100ms, TE = 6ms). Non-localized 31PMR spectra of the leg
(gastrocnemius/plantaris/soleus complex) were recorded using
an excitation block pulse of 100µs with a 45◦ flip angle, a 8012 Hz
sweep width, 4096 data points, 256 ms acquisition time, TR 5 s,
128 averages for CT1+/y and 400–512 averages for CT1−/y mice.
31P saturation transfer (ST) MRS experiments were performed to
derive the Pi→ATP (pseudo first order) forward rate constant kf
in the leg muscles (Nabuurs et al., 2010, 2013) using Gaussian
frequency selective saturation pulses (1000 points, duration
100 ms, selectivity ∼50 Hz) with pulse power optimization for
complete resonance saturation (∼370 rad/sec). Saturation was
applied at the γATP frequency and its mirror frequency around
the Pi peak using looped incremental saturation periods of 0.1,
0.2, 0.4, 0.6, 1.0, 1.5, and 3 s (Koretsky et al., 1985; Nabuurs et al.,
2010). Total TR was 5 s (2 s TR+ 3 s ST block) with 128 (CT1+/y)
or 512 (CT1−/y) averages.
From the single slice 2D-gradient echo MR images the muscle
CSA of the lower hind leg (mostly gastrocnemius-plantaris-
soleus) of CT1+/y (n = 5) and CT1−/y (n = 4) was determined
including a correction of the area occupied by bone (2 mm2).
From this corrected CSA and the βATP peak integral the ATP
tissue concentration in CT1−/y mice was estimated assuming
similar load of the RF coil by the hind legs of both mice and
a tissue [ATP] of 7.8 mM for CT1+/y mice (in ’t Zandt et al.,
2003; Nabuurs et al., 2013). The assessment of the integrals of
peaks and tissue pH from the PCr-Pi chemical shift in the 31P
MR spectra were done as described before (Nabuurs et al., 2010,
2013). From the PCr/ATP and Pi/ATP signal ratios we estimated
tissue levels of PCr and Pi after correction for T1 saturation.
For Pi a T1 of 1.95 s was applied (Nabuurs et al., 2010; Tyler
et al., 2010). T1 values, for PCr and βATP, derived from skeletal
muscle of 3 CT1+/y mice at 11.7T using inversion recovery, were
2.25 ± 0.118 and 0.656 ± 0.07 s, respectively. The muscle Pi→
ATP flux was obtained as the kf x [Pi] product (Nabuurs et al.,
2013).
Determination of Total Creatine
Total Cr levels were measured by HPLC from homogenized
samples with normalization to non-collagen protein, adapted
from Teerlink et al. (1993), as described previously (Zervou et al.,
2016).
Glucose Tolerance Tests
Mice were fasted for 14–16 h and intraperitoneally injected with
glucose (2 g per kg body weight). Blood glucose was measured
from tail capillary blood and collected at indicated times, as
previously described (Choe et al., 2013b). Experiments were
performed blinded.
Tissue Collection and Preparation
Animals were anesthetized with an intraperitoneal injection of
ketamine and xylazine or by 2–3% isoflurane in 100% oxygen.
Muscles were removed and flash frozen in liquid nitrogen. Lysates
were prepared in homogenization buffer containing phosphatase
inhibitors with disposable 1.5-mL pestles (VWR) and cleared by
centrifugation (Choe et al., 2013b). Protein concentrations were
determined using a BCATM protein assay (Thermo Scientific).
Western Blots
Equal amounts of cleared lysates (20–40 µg protein) were
separated by SDS-PAGE on precast gels (Invitrogen) and
transferred to nitrocellulose membrane. Antibodies against
AGAT (Santa Cruz), GAMT (Eurogentec), GLUT4 (Acris
Antibodies), Actin (Sigma Aldrich), UCP3 (Abcam), COX4 (Life
technologies), pAMPK, pACC, and AMPK (all Cell Signaling)
were used according to the manufacturers’ protocols. Enhanced
chemiluminescence (Luminata Crescendo, Millipore) signals
were detected with a luminescent image analyzer (LAS-4000,
FujiFilm). Total protein was measured with a laser scanner (FLA-
9000 with LPG filter, FujiFilm) on blot membranes stained with
Lava Purple (Fluorotechnics, Gel Company) according to the
manufacturer’s instructions. Signal quantification was performed
on non-saturated images using ImageJ software.
Statistical Analysis
Data are given as mean ± SEM. The following statistical tests
were applied: parametric t-test, one-way ANOVA or two-way
ANOVA followed by Newman–Keuls post hoc comparisons
(GraphPad Prism). All tests were two-tailed and the level of
significance was set at P < 0.05.
RESULTS
Reduced Creatine Levels in Skeletal
Muscle of CT1-Deficient Mice
Targeted disruption of the Slc6a8 gene in ESCs was employed
to prevent functional expression of CT1 protein (Figure 1A).
CT1−/y mice were born at the expected Mendelian ratio, were
viable and did not require any specific treatment for survival or
growth. In cDNA prepared from total RNA of skeletal muscle no
expression of the CT1 gene could be detected in CT1−/y mice
with gene specific PCR whereas a PCR product was observed
in CT1+/y mice (Figure 1B). HPLC-analysis revealed a 10-fold
reduction of Cr levels in heart and skeletal muscle, i.e., extensor
digitorum longus and soleus muscle (Table 1). Cerebral Cr levels
were also reduced, but only by about 70% (Table 1). No difference
of Cr levels was observed in kidney, which is the main organ
of endogenous Cr biosynthesis (Table 1). Expression of LacZ
revealed widespread activity of CT1 promoter in skeletal muscle
(Figures 1C,D). Thus, we successfully generated a CT1-deficient
mouse line for muscle phenotype analysis.
Cr Biosynthesis in Skeletal Muscle of
CT1-Deficient Mice
In rodents, only very low AGAT and GAMT activities were
found in skeletal muscle (Van Pilsum and Warhol, 1963; Daly,
1985). However, Cr deficiency has been shown to alter AGAT
protein expression. For example, GAMT-deficient mice display
compensatory upregulation of AGAT expression in kidney (Choe
et al., 2013a). Furthermore, AGAT expression in skeletal muscle
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FIGURE 1 | Generation and characterization of CT1-deficient mice. (A) The CT1 gene was disrupted by insertion of a SA-IRES-lacZ-neomycin cassette (tm1e allele).
(B) Total RNA prepared from muscle of CT1+/y and CT1−/y mice was reverse transcribed and then used for PCR amplification with primers specific for CT1
(expected band size: 250 bp). No amplification product for CT1 was observed in knockout mice. (C,D) Macroscopic (on a mm grid scale) and microscopic view of
hind limb muscle after LacZ staining indicating CT1 promoter activation.
TABLE 1 | HPLC-analysis of total creatine concentrations (mean ± SEM) in
CT1+/y and CT1−/y mice (n = 4 per tissue) (t-test, ∗∗∗P < 0.001).
Tissue Total creatine (nmol/mg protein)
CT1+/y CT1−/y
Heart 64.3 ± 6.6 4.5 ± 0.6∗∗∗
Brain 72.6 ± 9.5 22.5 ± 1.1∗∗∗
Skeletal muscle (extensor digitorum longus) 131.9 ± 6.7 16.1 ± 5.3∗∗∗
Skeletal muscle (soleus) 137.3 ± 9.9 15.7 ± 3.8∗∗∗
Kidney 12.3 ± 1.9 11.9 ± 3.8
was increased in another mouse model of CT1 deficiency
(Russell et al., 2014). Therefore, we studied AGAT and GAMT
protein expression in CT1-deficient mice for putative adaptive
changes. Quantitative western blot analysis revealed significant
upregulation of AGAT expression in kidney and skeletal muscle
of CT1−/y mice compared to wild-type mice (Figures 2A,B).
Furthermore, well-detectable GAMT expression was unaltered
in skeletal muscle of CT1−/y mice, whereas GAMT expression
in liver was even reduced in CT1−/y mice compared with
CT1+/y mice (Figures 2C,D). However, despite the strong
upregulation of AGAT protein expression, our data revealed
pronounced reduction of Cr in skeletal muscle of CT1−/y mice.
Thus, increased AGAT expression in skeletal muscle does not
compensate for the deficiency in skeletal muscle in CT1−/y mice.
CT1-Deficient Mice Reveal Reduced
Weight, Length, and Body Mass Index
L-Arginine:glycine amidinotransferase and GAMT deficiency in
transgenic mice leads to Cr-dependent failure to thrive with
reduced body weight and length (Schmidt et al., 2004; Choe
et al., 2013b). Similarly, CT1−/y mice were lean, short, and
had a markedly reduced body mass index (BMI) compared
with CT1+/y littermates (Figures 3A–D). CT1−/y mice showed
consistently lower body weight as early as from the age of 5 weeks
(Figure 3E). Overall, CT1−/y mice displayed morphometric
alterations indicative of severely impaired whole-body energy
homeostasis.
Impaired Motor Behavior in
CT1-Deficient Mice
Creatine transporter-deficient mice displayed reduced body
tension and severe kyphoscoliosis, suggesting pronounced
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FIGURE 2 | L-Arginine:glycine amidinotransferase and GAMT expression. Relative quantification of AGAT protein levels in kidney (A) and muscle (B) of CT1−/y mice
(n = 5–6). Relative quantification of GAMT protein levels in liver (C) and muscle (D) of CT1−/y mice (n = 6). Tissue samples of AGAT−/− and GAMT−/− mice to verify
antibody specificity (∗P < 0.05; ∗∗∗P < 0.001).
muscle weakness and chronic muscular hypotonia. Therefore,
we analyzed muscle function and motor behavior in detail.
Grip strength of CT1−/y mice was severely reduced to about
15% of that of CT1+/y littermates (grip strength: CT1+/y
1.63 ± 0.05 mN, CT1−/y 0.25 ± 0.01 mN, n = 9–15,
Figure 4A). In the rotarod test, latency to fall did not differ
between the two groups in the first trial. However, CT1+/y
littermates showed motor learning and increased performance
during subsequent trials, whereas CT1−/y mice remained at a
constantly low level (Figure 4B). During the pole test, CT1−/y
mice were not capable of turning upside down, whereas normal
performance was observed in almost all CT1+/y littermates
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FIGURE 3 | Morphometric parameters of CT1-deficient mice. Representative body morphology (A), snout-anus length (B), weight (C), and BMI (D) of 15-week-old
CT1+/y and CT1−/y male littermates (n = 5–6). (E) Body weight development in male animals until 15 weeks of age (n = 9–15) (∗∗P < 0.01; ∗∗∗P < 0.001).
(turning: CT1+/y: 8/9 mice, CT1−/y: 0/13 mice, Figure 4C).
In addition to strength, motor learning, and coordination, we
analyzed running endurance using an adapted voluntary wheel-
running system (De Bono et al., 2006). In contrast to CT1+/y
mice, the running distance of CT1−/y mice was dramatically
reduced (running distance: CT1+/y 8.41 ± 0.85 km/day, CT1−/y
1.99 ± 0.26 km/day, average of days 15–29, Figure 4D).
Taken together, CT1−/y mice displayed a motor phenotype
characterized by severe muscular hypotonia and kyphoscoliosis,
reduced muscle strength and low running endurance.
Muscle Atrophy in CT1-Deficient Mice
We analyzed the underlying cause of impaired motor function
of CT1−/y mice at MRI and histological levels. MRI of the hind
leg revealed reduced muscle CSAs in CT1−/y mice (CT1+/y
83.9± 3.0 mm2,CT1−/y 51.0± 3.0 mm2, n = 4–5, Figures 5A,B).
We then performed muscle histology to look if potential cell loss
or atrophy explains reduced muscle size. Single fiber atrophy
was detected in the extensor digitorum longus muscle, where
quantitative analysis revealed reduced myocyte CSAs in CT1−/y
mice compared with CT1+/y mice (CT1+/y 1466 ± 171.4 µm2,
CT1−/y 524.6 ± 22.86 µm2, n = 3, Figures 5C,D). Given
that CT1−/y mice have severe thoracolumbar kyphosis and
reduced muscle force during grip strength testing, both muscle
dysfunction and atrophy are likely to be present in all major
muscle groups.
CT1 Deficiency Improves Glucose
Tolerance
In a previous study, we detected a pronounced metabolic
phenotype in Cr-deficient AGAT−/− mice that was characterized
by improved glucose tolerance and resistance to diet-induced
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FIGURE 4 | Motor and behavioral phenotype of CT1-deficient mice. Grip strength (A), rotarod performance (B), successful turning in pole test (C), and voluntary
running distance (D) of CT1+/y and CT1−/y male littermates (n = 9–15) (∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001).
obesity (Choe et al., 2013b). Reduced body weight and altered
muscle physiology suggested similar metabolic alterations in
CT1−/y mice. Indeed, fasted and fed blood glucose levels
in CT1−/y mice were significantly decreased (fasted: CT1+/y
128.4 ± 4.67 mg/dl, CT1−/y 71.13 ± 3.14 mg/dl, fed: CT1+/y
152.3 ± 8.11 mg/dl, CT1−/y 122.9 ± 6.08 mg/dl, Figures 6A,B).
Furthermore, glucose tolerance tests revealed faster glucose
clearance in CT1−/y mice compared to CT1+/y mice after
normalization to fasted blood glucose levels (Figure 6C). As a
large proportion of glucose is taken up into skeletal muscle,
we analyzed the steady-state levels of glucose transporter
protein type 4 in skeletal muscle. Quantitative western blot
analysis revealed significantly increased GLUT4 levels in CT1−/y
mice (Figure 6D), which explains faster glucose clearance.
In addition, we detected reduced expression levels of UCP3
and a trend toward increased COX4 expression indicating
facilitated oxidative phosphorylation (Figure 6D). Furthermore,
citrate synthase activity – a measure of mitochondrial mass –
was significantly increased in extensor digitorum longus and
soleus muscle (Figure 6E). These findings suggest mitochondrial
content is increased to accelerate energy production to meet
increased energy demand. Given the imbalance between energy
demand and production, we looked for the activation of AMPK,
a key metabolic energy sensor and switch. Similar to GAMT
and AGAT mice, AMPK activation, as measured by phospho-
AMPK (pAMPK) or phosphorylated substrate (pACC) levels,
was increased in CT1−/y mice indicating a chronic catabolic
state, possibly resulting from energy deficiency, in skeletal muscle
(Figure 6F).
Reduced Phosphocreatine Levels and
Altered Muscle Energy Metabolism in
CT1-Deficient Mice
Our data indicate profound metabolic changes in muscle of CT1-
deficient mice. Therefore, we used muscle 31P MR spectroscopy
to obtain functional data on high energy phosphate turnover.
CT1−/y mice demonstrated a strong reduction of PCr in skeletal
muscle (Figure 7A). The PCr/Pi ratio was significantly reduced in
CT1−/y mice compared with CT1+/y mice (CT1+/y: 12.2 ± 0.7,
CT1−/y: 0.09 ± 0.02, P < 0.001, Figure 7B). Estimation of
PCr tissue concentrations in skeletal muscle revealed a 40-fold
reduction in CT1−/y mice (CT1+/y: 25.4 ± 0.1 mM, CT1−/y:
0.6 ± 0.1 mM, P < 0.001). In contrast to this decrease, the
Pi tissue concentration in skeletal muscle of CT1−/y mice
was increased threefold (CT1+/y: 2.16 ± 0.22 mM, CT1−/y:
6.6 ± 0.3 mM, P < 0.001). Furthermore, we determined whether
ATP levels were decreased in the hind limb of CT1−/y mice by
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FIGURE 5 | Muscle morphology and histology of CT1-deficient mice. (A) MR images for gross morphological analysis of hind limb muscles. (B) Cross-sectional area
of hind limb muscle (n = 4–5, ∗∗∗P < 0.001) determined by MRI. (C) Representative histological staining of extensor digitorum longus muscle. (D) Myocyte diameter
of extensor digitorum longus muscle (n = 3, ∗∗P < 0.01).
evaluating the signal intensity of ATP relative to the muscle CSA
(Nabuurs et al., 2013). Assuming a tissue concentration of 7.8mM
in wild-type skeletal muscle (in ’t Zandt et al., 2003), the ATP
concentration in CT1−/y hind limb muscle was estimated to be
4.2± 1.2 mM and therefore decreased by more than 40%. ATP/Pi
ratios were significantly reduced in CT1−/y mice, indicating
abnormal energy metabolism by contributing to a decreased
resting state phosphorylation potential due to the depletion of
PCr stores (CT1+/y: 3.87± 0.16, CT1−/y: 0.77± 0.06, P < 0.001,
Figures 7C–E). The calculated in vivo tissue pH was unaltered
between CT1+/y and CT1−/y mice. Next, we assessed kinetics of
ATP synthase in resting skeletal muscle from ST experiments.
The forward rate kf of ATP synthases in skeletal muscle of
CT1−/y mice was increased compared with CT1+/y mice, but
did not reach statistical significance (CT1+/y: 0.20 ± 0.04 s−1,
CT1−/y: 0.25 ± 0.05 s−1, P = 0.13) (Figure 7F). The trend
toward increased kf of ATP synthase in CT1
−/y mice indicates
increased total cytosolic and mitochondrial ATP synthetase
activity. Given the increased Pi tissue concentration in CT1−/y
mice, the Pi→ATP flux is increased in CT1−/y mice compared
with CT1+/y mice (CT1+/y: 0.43 ± 0.08 mM s−1, CT1−/y:
1.6 ± 0.3 mM s−1, P < 0.001) (Figure 7G). But, increased
Pi→ATP flux as a parameter of total ATP synthase activity at
rest is not sufficient to compensate for reduced ATP levels in
the absence of PCr. Taken together, changes in muscle function
and morphology of CT1−/y mice were associated with marked
alterations in energy metabolism, emphasizing the critical role of
CT1 in muscle physiology.
DISCUSSION
Our study revealed that CT1-deficient mice have a strongly
reduced skeletal muscle (P)Cr, an impaired motor function
with severe muscle atrophy, and increased glucose metabolism
due to AMPK activation. Major clinical problems in CT1-
deficient patients include behavioral abnormalities, seizures,
and intellectual impairment (Stockler et al., 2007). Therefore,
previous research was mainly focused on the effects of Cr
depletion in brain. In all available Cr-deficient mouse models,
however, pronounced muscular phenotypes were observed
(Schmidt et al., 2004; Nabuurs et al., 2013; Baroncelli et al., 2014;
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FIGURE 6 | Glucose metabolism and protein expression. (A,B) Fasted and fed blood glucose levels in CT1+/y and CT1−/y mice. (C) Glucose tolerance test
normalized to fasted blood glucose levels (n = 8–9). (D) Relative protein expression of muscle GLUT4, UCP3, and COX4 (n = 6). (E) Citrate synthase activity in
extensor digitorum longus (left) and soleus (right) muscle (n = 4–5). (F) Protein levels of pAMPK, pACC, and AMPK in muscle tissue (n = 6–8) (∗P < 0.05; ∗∗P < 0.01;
∗∗∗P < 0.001).
Russell et al., 2014). Here, we demonstrate strongly reduced
PCr levels in skeletal muscle of CT1-deficient mice resulting in
chronic energy depletion with increased resting Pi/ATP ratios.
Muscle physiology, metabolism, and morphology were severely
affected in CT1-deficient mice resulting in muscular atrophy and
thoracolumbar scoliosis.
Following synthesis in liver and kidney, Cr delivery to its
target organs such as muscle and brain is dependent on active
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FIGURE 7 | Muscle energy metabolism. (A) Representative 31P MR spectra of hind limb muscle in CT1+/y and CT1−/y mice (PCr, phosphocreatine; Pi, inorganic
phosphate; PMEs, phosphomonoesters; ppm, parts per million). (B) PCr/Pi ratios in CT1
+/y and CT1−/y mice measured with 31P MR spectroscopy (n = 4–5). (C,D)
Saturation transfer 31P MRS experiments on hind limb muscle of CT1+/y (A) and CT1−/y mice (B) to assess the Pi→ATP kinetics. The γATP peak is saturated (b)
and this saturation is transferred to the PCr and Pi peaks due to the creatine kinase and ATPase activity (subtraction spectra c = a minus b). This effect was used to
calculate the forward rate constant kf. ATP to free phosphate ratios (ATP/Pi) (E), kf values (F), and phosphate (Pi→ATP) flux (G) of hind limb muscle in CT1
+/y and
CT1−/y mice assessed with MR spectroscopy (n = 4–5) (∗∗P < 0.01; ∗∗∗P < 0.001).
transporters. To date, only CT1 encoded by SLC6A8 has been
identified as effective Cr transporter across cell membranes
(Abplanalp et al., 2013; van de Kamp et al., 2014). Consequently,
impaired CT1 activity has been associated with reduced cerebral
and muscular Cr levels (deGrauw et al., 2003; van de Kamp et al.,
2013). Here, we show that CT1 deficiency leads to markedly
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reduced Cr levels detected by HPLC-analysis and even stronger
reduced PCr levels with in vivo 31P MR spectroscopy in skeletal
muscle (Figures 1, 7). In previous studies on muscle of CT1-
deficient mice, however, residual Cr was reported from below
detection limit up to 23 or 36% of wild-type levels (Skelton et al.,
2011; Russell et al., 2014; Baroncelli et al., 2016). In addition,
two case studies on CT1-deficient patients showed almost normal
levels of Cr in skeletal muscle (deGrauw et al., 2003; Pyne-
Geithman et al., 2004). These discrepancies in muscular Cr
content might be explained by residual CT1 activity in affected
human patients (depending on the molecular nature of the
mutation) or by mouse strain differences. The differences in
Cr levels might also be due to specific detection techniques.
Photometric assays can be unspecific and overestimate Cr values
(Skelton et al., 2011; Russell et al., 2014).
An alternative explanation for residual Cr levels in muscle
and brain of CT1-deficient animals as well as patients might be
endogenous Cr synthesis. Under healthy or normal physiological
conditions, AGAT levels are low in skeletal muscle (Figure 2).
Cr synthesis is thought to take place almost exclusively in liver
and kidney, with a minor contribution from pancreas (Wyss
and Kaddurah-Daouk, 2000; Brosnan and Brosnan, 2010; da
Silva et al., 2014). However, AGAT expression is regulated by Cr
availability in a negative feedback loop (Choe et al., 2013a; Russell
et al., 2014). Indeed, we detected increased AGAT expression in
skeletal muscle following intracellular Cr depletion due to CT1
deficiency (Figure 2). As PCr levels remained low despite GAMT
and increased AGAT expression, endogenous Cr synthesis in
muscle was insufficient to compensate for CT1 deficiency in our
mouse model. Thus, CT1 deficiency in mice induces a strong
decrease in Cr in muscle, despite compensatory upregulation of
enzymes involved in Cr synthesis.
Skeletal muscle contains Cr in concentrations of up to 40 mM.
Accordingly, muscle physiology was severely affected in Cr-
deficient CT1−/y mice. Reduced muscle force and endurance
as well as pronounced kyphoscoliosis demonstrate generalized
impairment of muscle function (Figure 5). These functional
alterations were accompanied by structural changes such as
a reduction in muscle and myocyte diameter, which is in
line with reports describing a close correlation of muscle
diameter and contractile power (Maughan et al., 1983a,b).
Absolute numbers of myocytes were not quantified, but similar
reductions in muscle and myocyte diameters do not suggest
a reduction in the overall number of myocytes. A reduced
myocyte diameter can be explained by Cr deficiency itself and by
chronic energy depletion and involvement of catabolic pathways
including AMPK activation. Previous studies on AGAT-
and GAMT-deficient mice showed ultrastructural changes in
muscle histology, including lipid droplets around mitochondria
(Schmidt et al., 2004; Nabuurs et al., 2013). Also AGAT-
deficient muscle displayed a transcriptomic signature resembling
a transcriptional response known as the mitochondrial unfolded
protein response (Stockebrand et al., 2016; Shpilka and
Haynes, 2018). Neither ultrastructural analysis of skeletal muscle
nor transcriptomic analyses have been performed in CT1-
deficient mice yet, but similar processes are likely to be
involved.
Motor behavior in CT1-deficient mice was impaired not
only in terms of muscle force but also wheel running
distance and motor learning (Figure 5). Reduced wheel running
might partly be explained by low muscle force, but also by
deficient energy stores and impaired oxidative phosphorylation
(see below). During rotarod testing for motor learning and
coordination, performance during the first trial did not differ
from CT1+/y mice because low body weight might compensate
for reduced muscle strength. However, unlike CT1+/y mice, the
performance of CT1−/y mice did not improve during subsequent
trials indicating not only peripheral muscular but also CNS
contribution to the motor phenotype.
Severely altered structure and function of skeletal muscle were
also observed in Cr-deficient AGAT knockout mice, whereas
GAMT knockout mice displayed a milder muscular phenotype
most likely due to high levels of guanidinoacetate that, although
being a weak substrate for creatine kinase, can be phosphorylated
and partly substitute for Cr (Schulze et al., 2003; Ensenauer
et al., 2004; Kan et al., 2004). Some muscle properties derived
from 31P MRS data show strikingly similar differences with
WT between AGAT and CT1 knockouts: in both PCr was
dramatically reduced with a concomitant decrease of ATP by
40%. This resulted in ametabolic remodeling including a fourfold
increased Pi/ATP at an unchanged tissue pH (Nabuurs et al.,
2013). The observed stronger reduction in PCr (40-fold) than
in total Cr (10-fold) would be in agreement with a creatine
kinase equilibrium shift due to the lower ATP level. Apparently,
despite increased Pi→ATP flux the muscles of CT1−/y mice
cannot maintain normal ATP levels, even in the resting state.
Reduced ATP and increased Pi levels result in chronic AMPK
activation indicating a catabolic state favoring energy production.
Accordingly, mitochondrial volume is increased and oxidative
phosphorylation is accelerated, but not sufficient to normalize
ATP levels. In line with these findings, creatine-deficient muscle
in AGAT−/− mice revealed increased absolute mitochondrial
mass, but decreased respiratory chain enzyme activities per
mitochondrial content (i.e., citrate synthase activity) (Nabuurs
et al., 2013).
Both functional (reduction in grip strength: 70% for
AGAT−/− vs. 85% in CT1−/y) and structural changes (reduction
in myocyte diameter: 35% for AGAT−/− vs. 65% in CT1−/y)
were even more pronounced in CT1−/y mice compared with
AGAT−/− mice (Figures 4A, 5D) (Nabuurs et al., 2013). PCr
levels in adult mice measured by MRS were low both in
AGAT−/− and CT1−/y mice and cannot explain the differences.
However, it has to be considered that mice from both lines
were exposed to high maternal Cr levels during pregnancy and
lactation. In AGAT−/− mice, Cr can be taken up into the target
organs by CT1 and may compensate for deficient endogenous
Cr synthesis to a certain extent. In CT1 deficiency, a lack of
functional Cr transporters prevents normalization of Cr stores
in muscle, even following high serum Cr levels throughout
intrauterine and postnatal development. Hence, intracellular Cr
deficiency during early development seems to play a critical role
for the outcome of genetic Cr deficiency.
Cerebral creatine deficiency in mice resulted in cognitive
impairment and neuropathological abnormalities, which might
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also contribute to the muscle phenotype of systemic CT1-
deficient mice (Kurosawa et al., 2012; Baroncelli et al., 2016).
But skeletal muscle of mouse models deficient in muscle creatine
kinase lacked burst activity, revealed altered intracellular calcium
release and increased fatigue with tetanic stimulation (van
Deursen et al., 1993; Steeghs et al., 1997, 1998; Dahlstedt et al.,
2000). In the absence of PCr/Cr buffering, in vivoMRS studies of
muscle energetics revealed that ATP levels, pH and Pi levels could
not be maintained during ischemic conditions despite increased
glycolytic ATP synthesis (in ’t Zandt et al., 1999, 2003; Nabuurs
et al., 2013). Therefore, creatine deficiency in skeletal muscle per
se impairs energy metabolism and motor function independent
of neuronal dysfunction.
Limitations of our study are that we cannot rule out that
developmental alterations are also responsible for impaired
motor function. Given that mice with CT1 deficiency revealed
age-related progressive cognitive impairment associated with
brain aging, motor behavior could also be altered due
to developmental disturbances (Baroncelli et al., 2016).
Furthermore, in our systemic CT1-deficient mouse models,
we are unable to clearly differentiate neuronal and muscular
contributions to motor function. Given that brain-specific CT1
deficiency in mice recapitulates some metabolic and cognitive
characteristics, a contribution of neuronal creatine deficiency
to motor function is possible (Kurosawa et al., 2012; Baroncelli
et al., 2016). But other mouse models with disrupted PCr/Cr
buffering (i.e., deficiency of AGAT, cytosolic or mitochondrial
creatine kinase) clearly link muscle creatine deficiency with
motor dysfunction.
Although cognitive impairment and developmental delay are
the hallmarks of human Cr deficiency syndromes, muscular
hypotonia and myopathy were also described in patients with
AGAT, GAMT, and CT1 deficiency (Stockler et al., 1996; Anselm
et al., 2006; Nouioua et al., 2013). The overt muscular phenotype
in Cr-deficient mouse models, however, has not been observed
in humans. In contrast to mice, human patients still ingest
Cr via their normal diet. However, oral Cr supplementation is
only feasible in AGAT and GAMT deficiency, but proved to be
ineffective in CT1 deficiency (Stockler et al., 2007). Expression of
AGAT is upregulated in muscle of CT1-deficient mice (Figure 2).
It is possible that this compensatory mechanism is sufficient
to maintain endogenous Cr synthesis in human patients. To
our knowledge, AGAT and GAMT expression in patients has
not yet been directly assessed, for example by muscle biopsy.
Although impaired skeletal muscle function does not seem to be a
critical symptom inmost CT1-deficient patients, low intracellular
PCr/Cr energy stores might further compromise muscle function
and increase the risk of muscle damage in situations of metabolic
stress such as infections or intensified exercise in CT1-deficient
patients. In summary, CT1 deficiency results in reduced levels
of high energy phosphates (PCr, ATP), muscle weakness and
atrophy, despite compensatory mechanisms of creatine and ATP
biosynthesis.
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